Ethacrynic acid is an unsaturated ketone derivative of an aryloxyacetic acid.
EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.
- Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
- Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
- Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.
- Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.
Published Studies Related to Edecrin (Ethacrynic Acid)
A comparison of the effects of inhaled furosemide and ethacrynic acid on sodium-metabisulfite-induced bronchoconstriction in subjects with asthma. [1995.02]
Inhaled furosemide prevents bronchoconstriction induced by a number of challenges in asthma. One approach to determine the mechanism underlying this protection has been to examine the effects of diuretics with different or overlapping pharmacologic effects... This suggests that interaction with the Na/K/Cl cotransporter protein, or carbonic anhydrase inhibition, is not relevant to the effects of furosemide in asthma.
Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. [1994.09]
Ethacrynic acid (EA) is an inhibitor of the glutathione S-transferases (GSTs), a family of detoxification enzymes the expression of which has been associated with resistance to several classes of anticancer drugs. We performed a two-way randomized crossover study to investigate the pharmacokinetics and bioavailability of EA and describe any toxicities of EA associated with i.v.
Alternating sequential dosing with furosemide and ethacrynic acid in drug tolerance in the newborn. [1989.07]
Drug tolerance seems to develop rapidly after the administration of sequential doses of the same loop diuretic. We evaluated whether alternating different loop diuretics could achieve the same initial diuretic response in the newborn... In conclusion, consecutive alternation of furosemide and ethacrynic acid in the same newborn does not prevent the development of pharmacologic tolerance to loop diuretics, since diuresis, natriuresis, and chloriuresis decrease after successive sequential administration of these drugs.
Inhibitory effects of ethacrynic acid analogues lacking the alpha,beta-unsaturated carbonyl unit and para-acylated phenols on human cancer cells. [2011.02.01]
A series of ethacrynic acid analogues, lacking the alpha,beta-unsaturated carbonyl unit, was synthesized and subsequently evaluated for their ability to inhibit the migration of human breast cancer cells, Hs578Ts(i)8 as well as of human prostate cancer cells, C4-2B.Our studies show that ethacrynic acid analogues with methyl substituents at the aromatic ring demonstrate no inhibitory effect on the migration of both cancer cell lines, whereas a precursor in the synthesis of these ethacrynic acid analogues (II-1, a para-acylated m-cresol) is an excellent inhibitor of the migration of both cancer cell lines.
Influence of ethacrynic acid on the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock seizure model. [2010.09]
The aim of this study was to determine whether ethacrynic acid (EA), a loop diuretic with anticonvulsant activity, would affect the protective action of the conventional antiepileptics (AEDs) carbamazepine (CBZ), phenytoin (PHT), valproate (VPA) and phenobarbital (PB) in the mouse maximal electroshock seizure (MES) model...
Clinical Trials Related to Edecrin (Ethacrynic Acid)
Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease [Recruiting]
Novel Drug Delivery Technique Via Retroject Device [Recruiting]
The purpose of this study is to identify whether or not injection of a study drug
(ethacrynic acid) using the investigational Retroject device is able to lower eye pressures
in patients with advanced glaucoma. 20 patients with advanced glaucoma with visual acuity
less than 20/200 and intraocular pressures (IOP) >20mmHg on maximum medical therapy will be
asked to participate in the study. The first five patients will have the Retroject device
placed over their eye for 30 seconds and then removed. Assuming no issues, then it will be
placed on the eye for one minute. The second group of patients (3 total) will have the
Retroject device placed on the eye and then an injection of ethacrynic acid into the
episcleral vein. The third group of patients (12 total) will have the Retroject device
placed on the eye and then will be randomized in a 2: 1 ratio to receive either an ethacrynic
acid injection or a balanced salt solution injection. All 20 patients will then return for
intraocular pressure measurements on days 1, 2, 3, and 7 as well as 6 weeks after injection.
In addition, the patients will undergo pre and post intervention corneal endothelial
assessments (endothelial cell count, shape analysis, and pachymetry). Potential safety
issues are unlikely and include bleeding, infection, pain, ototoxicity, or temporary or
permanent loss of vision.
Page last updated: 2011-12-09